Product Description
Reteplase (BM 06.022; r-PA) is a recombinant peptide which consists of the kringle 2 and protease domains of human tissue-type plasminogen activator. It has been developed as a thrombolytic treatment for acute myocardial infarction (AMI). (Sourced from: https://pubmed.ncbi.nlm.nih.gov/8891469/)
Mechanisms of Action: PLA Activator
Novel Mechanism: No
Modality: Coagulation Factor
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Austria | Bangladesh | Belgium | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Estonia | European Medicines Agency | Finland | Germany | Greece | Hong Kong | Hungary | Iceland | India | Ireland | Italy | Latvia | Lithuania | Luxembourg | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Slovakia | Spain | Sweden | Turkey | United Kingdom | United States
Approved Indications: None
Known Adverse Events: None
Company: Chiesi
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 2
Highest Development Phases
Phase 3: Ischemic Stroke|Thrombosis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| READY 1 | P3 |
Active, not recruiting |
Thrombosis |
2021-12-04 |
|
| CTR20213294 | P3 |
Recruiting |
Ischemic Stroke |
None |